ORPHA:1164
Allergic bronchopulmonary aspergillosis
Also known as: ABPA · Allergic aspergillosis · Hinson-Pepys disease
Publications
6,854
Trials
20
Interventional, condition-specific
Researchers
1,118
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare immunologic pulmonary disorder caused by hypersensitivity to Aspergillus fumigatus, clinically manifesting with poorly controlled asthma and recurrent pulmonary infiltrates.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015243
- MeSH:D001229
- OMIM:103920
- UMLS:C3278302
- NCIT:C84547
Additional Mondo synonyms (1)
allergic aspergillosis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
6,854 matched papers (3,844 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
20 matched on ClinicalTrials.gov (3 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
6,854
6,854 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
6,854 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
3,844 in the last 10 years · low confidence
Phrase hits: 6,854 · MeSH hits: 0
Who's working on it?
1,118
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Agarwal R22 papers · 2026
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. agarwal.ritesh@outlook.in.
Papers in Europe PMC - 02Sehgal IS18 papers · 2026
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Papers in Europe PMC - 03Muthu V17 papers · 2026
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Papers in Europe PMC - 04Dhooria S10 papers · 2026
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Papers in Europe PMC - 05Prasad KT9 papers · 2026
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Papers in Europe PMC - 06Aggarwal AN8 papers · 2026
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Papers in Europe PMC - 07
- 08Garg M7 papers · 2026
Department of Radiodiagnosis, Postgraduate Institute of Medical Education and Research (PGIMER), Sector-12, Chandigarh, 160012, India.
Papers in Europe PMC - 09Rudramurthy SM7 papers · 2026
Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Papers in Europe PMC - 10Li Y6 papers · 2026
Department of Allergy, The First Hospital of Hohhot, Hohhot, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
20
interventional trials for this specific condition
20 interventional trials matched this specific condition name; 3 currently recruiting in our sample. 103 trials are registered for aspergillosis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
20 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 94.5th percentile).
low confidence · 94.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
20 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06174922·RECRUITING·A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis
Conditions: Allergic Bronchopulmonary Aspergillosis·Matched via name phrase
- NCT06244979·RECRUITING·iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine
Conditions: Pulmonary Aspergillosis · Chronic Pulmonary Aspergillosis · Allergic Bronchopulmonary Aspergillosis·Matched via name phrase
- NCT05444946·RECRUITING·Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome
Conditions: Chronic Pulmonary Aspergillosis · Allergic Bronchopulmonary Aspergillosis·Matched via name phrase
Broader category: aspergillosis
103
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05653193·RECRUITING·Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study
Conditions: Chronic Pulmonary Aspergillosis · Aspergillosis·Matched via name phrase
- NCT07337720·NOT YET RECRUITING·Liposomal Amphotericin B in Invasive Aspergillosis With Hepatic Dysfunction
Conditions: Aspergillosis Invasive·Matched via name phrase
- NCT07530263·NOT YET RECRUITING·Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA)
Conditions: Chronic Pulmonary Aspergillosis·Matched via name phrase
- NCT06440915·RECRUITING·Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children
Conditions: Aspergillosis Invasive · Mucormycosis·Matched via name phrase
- NCT03656081·RECRUITING·Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole
Conditions: Chronic Pulmonary Aspergillosis·Matched via name phrase
- NCT06447402·RECRUITING·A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary Aspergillosis
Conditions: Chronic Pulmonary Aspergillosis · CPA · Aspergilloma·Matched via name phrase
- NCT03828773·RECRUITING·PTX3-targeted Antifungal Prophylaxis
Conditions: Candidiasis · Fungal Infection · Acute Myeloid Leukemia · Genetic Predisposition·Matched via name phrase
- NCT06582186·NOT YET RECRUITING·Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm
Conditions: Aspergillosis Invasive · Fungal Infection · Hematologic Malignancy·Matched via name phrase
- NCT03717623·RECRUITING·Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
Conditions: Posaconazole · Pharmacokinetics · Invasive Candidiases · Invasive Aspergillosis·Matched via name phrase
Observational and natural-history studies
17 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06645210·NOT YET RECRUITING·Multicenter Registration Study on Allergic Bronchopulmonary Aspergillosis
Conditions: Allergic Bronchopulmonary Aspergillosis·Matched via name phrase
- NCT07362667·RECRUITING·A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA
Conditions: ABPA · Allergic Bronchopulmonary Aspergillosis · Allergic Bronchopulmonary Aspergillosis (ABPA) · Airway Clearance·Matched via name phrase
- NCT07530770·RECRUITING·Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis
Conditions: Allergic Bronchopulmonary Aspergillosis · Severe Asthma · ABPA·Matched via name phrase
- NCT07690345·RECRUITING·Fungal Status and Prognosis in ABPA
Conditions: ABPA · Allergic Bronchopulmonary Aspergillosis · Allergic Bronchopulmonary Aspergillosis (ABPA) · Colonization·Matched via name phrase
- NCT07362693·RECRUITING·A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA
Conditions: ABPA · Biologics · Allergic Bronchopulmonary Aspergillosis (ABPA) · Cohort Study·Matched via name phrase
- NCT07611838·RECRUITING·Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction
Conditions: Allergic Bronchopulmonary Aspergillosis (ABPA) · Machine Learning · Multi-omics · Multicenter Study·Matched via name phrase
- NCT07493629·RECRUITING·Immune Status and Disease Control of Inflammatory Airway Diseases
Conditions: Airway Inflammation · Chronic Obstructive Pulmonary Disease (COPD) · Asthma (Diagnosis) · Bronchiectasis·Matched via name phrase
- NCT07040332·RECRUITING·Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis
Conditions: Allergic Bronchopulmonary Aspergillosis (ABPA)·Matched via name phrase
- NCT07714863·RECRUITING·ML-Based ABPA Recurrence Prediction and Clinical Utility
Conditions: ABPA · Allergic Bronchopulmonary Aspergillosis · Allergic Bronchopulmonary Aspergillosis (ABPA) · Acute Exacerbation·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Allergic bronchopulmonary aspergillosis" OR "Allergic aspergillosis" OR "Hinson-Pepys disease"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Allergic bronchopulmonary aspergillosis" OR "Allergic aspergillosis" OR "Hinson-Pepys disease"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 20 interventional · 17 observational · 1 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"aspergillosis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: ABPA
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (6854) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T16:33:09.707Z
